PrimCareIT

Purchase Zaleplon (Sonata) tablets online on PrimCareIT



How and where to order Sonata (Zaleplon) sleep aid pills online:

Shop: SPECIALTY PHARMACY

Prices: from $1.51 per pill

Forms: Sonata (Zaleplon) 10 mg tablets

Quantity: 30-300 pills

Type: Zaleplon brand, Sonata generic

Payment: Visa, MasterCard, Bitcoin

Delivery: International delivery service

Shipping: Worldwide, including USA, Europe, Canada, Australia


Zaleplon (trade names include Sonata, Andante, Starnoc, Zerene, Zonesta) is a hypnotic and sedative medication from benzodiazepine related drugs pharmacological group. This medicine is used for the short-term treatment of insomnia, difficulty falling and stay asleep. It works by affecting some chemicals in brain that may become unbalanced and cause sleep problems (insomnia).


Sonata (Zaleplon)


Related medications:

  • Alprazolam (Xanax)
  • Apronal (Sedormid)
  • Butobarbital (Soneryl)
  • Chloral Hydrate (Chloraldurat)
  • Chloralodol (Mechloral)
  • Dexmedetomidine (Precedex)
  • Diazepam (Valium)
  • Eszopiclone (Lunesta)
  • Flunitrazepam (Rohypnol)
  • Lorazepam (Ativan)
  • Melatonin (Circadin)
  • Methylpentynol (Dormison)
  • Midazolam (Versed)
  • Modafinil (Provigil)
  • Niaprazine (Nopron)
  • Nitrazepam (Mogadon)
  • Pentobarbital (Nembutal)
  • Pyrithyldione (Presidon)
  • Ramelteon (Rozerem)
  • Tasimelteon (Hetlioz)
  • Temazepam (Restoril)
  • Zolpidem (Ambien)
  • Zopiclone (Imovane)


    Pharmacological and medical categories:

  • Anti-insomnia medicines
  • Anxiolytics
  • Hypnotics
  • Nonbenzodiazepines
  • Pyrazolopyrimidines
  • Sedatives
  • Sleep aid medications
  • Z-drugs


    ATC codes:

  • N - Nervous system
  • N05 - Psycholeptics
  • N05C - Hypnotics and sedatives
  • N05CF - Benzodiazepine related drugs
  • N05CF03 - Zaleplon


    ICD-10 codes:

  • Nonorganic sleep disorders - F51
  • Sleep disorders - G47


    Indications and usage:

    Sonata (Zaleplon) is indicated for the short-term treatment of insomnia. Sonata has been shown to decrease the time to sleep onset for up to 30 days in controlled clinical studies. It has not been shown to increase total sleep time or decrease the number of awakenings. The clinical trials performed in support of efficacy ranged from a single night to 5 weeks in duration. The final formal assessments of sleep latency were performed at the end of treatment.


    Dosage and administration:

    The dose of Sonata should be individualized. The recommended dose of Zaleplon pills for most nonelderly adults is 10 mg. For certain low weight individuals, 5 mg may be a sufficient dose. Although the risk of certain adverse events associated with the use of Sonata appears to be dose dependent, the 20 mg dose has been shown to be adequately tolerated and may be considered for the occasional patient who does not benefit from a trial of a lower dose. Doses above 20 mg have not been adequately evaluated and are not recommended.

    Zaleplon (Sonata) should be taken immediately before bedtime or after the patient has gone to bed and has experienced difficulty falling asleep. Taking Sonata with or immediately after a heavy, high-fat meal results in slower absorption and would be expected to reduce the effect of Sonata on sleep latency.


    Dosage forms and strengths:

    Sonata (Zaleplon) capsules 5 mg: opaque green cap and opaque pale green body with "5 mg" on the cap and "SONATA" on the body.

    Sonata (Zaleplon) capsules 10 mg: opaque green cap and opaque light green body with "10 mg" on the cap and "SONATA" on the body.


    Overdosage:

    Signs and symptoms

    Signs and symptoms of overdose by Sonata (Zaleplon) capsules effects of CNS depressants can be expected to present as exaggerations of the pharmacological effects noted in preclinical testing. Overdose is usually manifested by degrees of central nervous system depression ranging from drowsiness to coma. In mild cases, symptoms include drowsiness, mental confusion, and lethargy; in more serious cases, symptoms may include ataxia, hypotonia, hypotension, respiratory depression, rarely coma, and very rarely death.

    Loss of consciousness, in addition to signs and symptoms consistent with CNS depressants as described above, have been reported following zaleplon overdose. Individuals have fully recovered from zaleplon overdoses of greater than 200 mg (10 times the maximum recommended dose of zaleplon). Rare instances of fatal outcomes following overdose with zaleplon, most often associated with overdose of additional CNS depressants, have been reported.

    Recommended treatment

    General symptomatic and supportive measures should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. Animal studies suggest that flumazenil is an antagonist to zaleplon. However, there is no pre-marketing clinical experience with the use of flumazenil as an antidote to a Sonata overdose. As in all cases of drug overdose, respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. Hypotension and CNS depression should be monitored and treated by appropriate medical intervention.

    Poison control center

    As with the management of all overdosage, the possibility of multiple drug ingestion should be considered. The physician may wish to consider contacting a poison control center for up-to-date information on the management of hypnotic drug product overdosage.


    Contraindications:

    Hypersensitivity to zaleplon or any excipients in the formulation.


    Warnings:

  • Complex sleep behaviors
  • CNS-Depressant effects and next-day impairment
  • Need to evaluate for co-morbid diagnoses
  • Severe anaphylactic and anaphylactoid reactions
  • Abnormal thinking and behavioral changes
  • Withdrawal effects


    Precautions:

    Timing of drug administration

    Zaleplon (Sonata) should be taken immediately before bedtime or after the patient has gone to bed and has experienced difficulty falling asleep. As with all sedative/hypnotics, taking Sonata while still up and about may result in short-term memory impairment, hallucinations, impaired coordination, dizziness, and lightheadedness.

    Use in the elderly and/or debilitated patients

    Impaired motor and/or cognitive performance after repeated exposure or unusual sensitivity to sedative/hypnotic drugs is a concern in the treatment of elderly and/or debilitated patients. A dose of 5 mg is recommended for elderly patients to decrease the possibility of side effects. Elderly and/or debilitated patients should be monitored closely.

    Use in patients with concomitant illness

    Clinical experience with Sonata (Zaleplon) in patients with concomitant systemic illness is limited. Sonata should be used with caution in patients with diseases or conditions that could affect metabolism or hemodynamic responses.

    Although preliminary studies did not reveal respiratory depressant effects at hypnotic doses of this medication in normal subjects, caution should be observed if Sonata (Zaleplon) is prescribed to patients with compromised respiratory function, because sedative/hypnotics have the capacity to depress respiratory drive. Controlled trials of acute administration of Sonata 10 mg in patients with mild to moderate chronic obstructive pulmonary disease or moderate obstructive sleep apnea showed no evidence of alterations in blood gases or apnea/hypopnea index, respectively. However, patients with compromised respiration due to preexisting illness should be monitored carefully.

    The dose of zaleplon should be reduced to 5 mg in patients with mild to moderate hepatic impairment. It is not recommended for use in patients with severe hepatic impairment.

    No dose adjustment is necessary in patients with mild to moderate renal impairment. Sonata has not been adequately studied in patients with severe renal impairment.

    Use in patients with depression

    In primarily depressed patients treated with sedative-hypnotics, worsening of depression, including suicidal thoughts and actions (including completed suicides), have been reported. As with other sedative/hypnotic drugs, this drug should be administered with caution to patients exhibiting signs or symptoms of depression. Suicidal tendencies may be present in such patients and protective measures may be required. Intentional overdosage is more common in this group of patients; therefore, the least amount of drug that is feasible should be prescribed for the patient at any one time.

    Allergic-Type Reactions FD&C Yellow No. 5

    This product contains FD&C Yellow No. 5 (Tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (Tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.


    Drug interactions:

    As with all drugs, the potential exists for interaction of zaleplon with other drugs by a variety of mechanisms.

  • CNS-active drugs (ethanol, imipramine, paroxetine, thioridazine, venlafaxine, promethazine)
  • Drugs that induce CYP3A4 (rifampin)
  • Drugs that inhibit CYP3A4
  • Drugs that inhibit aldehyde oxidase (diphenhydramine)
  • Drugs that inhibit both aldehyde oxidase and CYP3A4 (cimetidine)
  • Drugs highly bound to plasma protein
  • Drugs with a narrow therapeutic index (digoxin, warfarin)
  • Drugs that alter renal excretion (ibuprofen)


    Adverse reactions, side effects:

    Most common adverse reactions of Sonata (Zaleplon) tablets:

  • Abdominal pain
  • Abnormal vision
  • Amnesia
  • Anorexia
  • Asthenia
  • Colitis
  • Confusion
  • Depersonalization
  • Dizziness
  • Dysmenorrhea
  • Ear pain
  • Epistaxis
  • Eye pain
  • Hallucinations
  • Headache
  • Hyperacusis
  • Hypertonia
  • Hypesthesia
  • Malaise
  • Nausea
  • Paresthesia
  • Parosmia
  • Peripheral edema
  • Photosensitivity reaction
  • Somnolence
  • Tremor
  • Vertigo


    Use in specific populations:

    Pregnancy

    In embryofetal development studies in rats and rabbits, oral administration of up to 100 mg/kg/day and 50 mg/kg/day, respectively, to pregnant animals throughout organogenesis produced no evidence of teratogenicity. These doses are equivalent to 49 (rat) and 48 (rabbit) times the maximum recommended human dose (MRHD) of 20 mg on a mg/m2 basis. In rats, pre- and postnatal growth was reduced in the offspring of dams receiving 100 mg/kg/day. This dose was also maternally toxic, as evidenced by clinical signs and decreased maternal body weight gain during gestation. The no-effect dose for rat offspring growth reduction was 10 mg/kg (a dose equivalent to 5 times the MRHD of 20 mg on a mg/m2 basis). No adverse effects on embryofetal development were observed in rabbits at the doses examined.

    In a pre- and postnatal development study in rats, increased stillbirth and postnatal mortality, and decreased growth and physical development, were observed in the offspring of females treated with doses of 7 mg/kg/day or greater during the latter part of gestation and throughout lactation. There was no evidence of maternal toxicity at this dose. The no-effect dose for offspring development was 1 mg/kg/day (a dose equivalent to 0.5 times the MRHD of 20 mg on a mg/m2 basis). When the adverse effects on offspring viability and growth were examined in a cross-fostering study, they appeared to result from both in utero and lactational exposure to the drug.

    There are no studies of zaleplon in pregnant women; therefore, Sonata (Zaleplon) is not recommended for use in women during pregnancy.

    Labor and delivery

    Zaleplon has no established use in labor and delivery.

    Nursing mothers

    A study in lactating mothers indicated that the clearance and half-life of zaleplon is similar to that in young normal subjects. A small amount of zaleplon is excreted in breast milk, with the highest excreted amount occurring during a feeding at approximately 1 hour after Sonata administration. Since the small amount of the drug from breast milk may result in potentially important concentrations in infants, and because the effects of zaleplon on a nursing infant are not known, it is recommended that nursing mothers not take this medication.

    Pediatric use

    The safety and effectiveness of Sonata (Zaleplon) capsules in pediatric patients have not been established.

    Geriatric use

    A total of 628 patients in double-blind, placebo-controlled, parallel-group clinical trials who received Sonata were at least 65 years of age; of these, 311 received 5 mg and 317 received 10 mg. In both sleep laboratory and outpatient studies, elderly patients with insomnia responded to a 5 mg dose with a reduced sleep latency, and thus 5 mg is the recommended dose in this population. During short-term treatment (14 night studies) of elderly patients with zaleplon, no adverse event with a frequency of at least 1% occurred at a significantly higher rate with either 5 mg or 10 mg Sonata than with placebo.


    Pregnancy categories:

  • B2 - Australia
  • C - United States (Risk cannot be ruled out)


    Salts and other forms:

  • Zaleplon Base


    Synonyms, international and chemical names:

  • 3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide
  • Acetamide, N-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethyl-
  • N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide
  • Tsaleploni
  • Zaleplone
  • Zaleploni
  • Zaleplonum


    Brands, generics, trade names:

  • Andante - Gedeon Richter
  • Morfeo - Polfa Pabianice, Adamed
  • Rhem - Andromaco Laboratorios
  • Siesta - Al Andalous Medical Company, Incepta Pharmaceuticals
  • Sleep Aid - October Pharma
  • Sonata - Pfizer
  • Starnoc - Pfizer
  • Zalep - Cipla, Protec
  • Zaleplon - Aurobindo, Mylan, Roxane Laboratories, Sandoz, Teva
  • Zaplon - Torrent Pharmaceuticals
  • Zerene - Pfizer
  • Zonesta - Intas Pharmaceuticals


    Here is a list of popular medications containing zaleplon as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

    Trade name of the drug Pharmaceutical forms and doses Companies
    Andante
  • Capsules; Oral; Zaleplon 5 mg
  • Capsules; Oral; Zaleplon 10 mg
  • Gedeon Richter
  • Sonata
  • Capsules; Oral; Zaleplon 5 mg
  • Capsules; Oral; Zaleplon 10 mg
  • Pfizer
  • Jones Pharma
  • King Pharmaceuticals
  • Meda
  • Uriach
  • Wyeth
  • Starnoc
  • Capsules; Oral; Zaleplon 5 mg
  • Capsules; Oral; Zaleplon 10 mg
  • Pfizer
  • Servier
  • Zerene
  • Capsules; Oral; Zaleplon 5 mg
  • Capsules; Oral; Zaleplon 10 mg
  • Pfizer
  • Meda
  • Medinet Pharmaceuticals
  • Sigma-Tau Pharmaceuticals
  • Vivian Corporation
  • Wyeth
  • Zonesta
  • Capsules; Oral; Zaleplon 10 mg
  • Intas Pharmaceuticals



  • References:

  • Zaleplon main article on Wikipedia: https://en.wikipedia.org/wiki/Zaleplon
  • Zaleplon compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/5719
  • Zaleplon on DrugBank: https://go.drugbank.com/drugs/DB00962
  • Zaleplon FAQ on MedlinePlus (revised 12/15/2019): https://medlineplus.gov/druginfo/meds/a601251.html
  • Sonata (Zaleplon) capsules drug label info on DailyMed (revised May 27, 2010): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
  • Zaleplon capsules drug label info on DailyMed (revised September 6, 2019): https://dailymed.nlm.nih.gov/dailymed/lookup...
  • Zaleplon international drug names on Drugs.com: https://www.drugs.com/international/zaleplon.html
  • Zaleplon for sale on Pharma Doctor: https://pharma-doctor.com/zaleplon.html
  • Zaleplon containing drugs on Drugs-About.com: https://drugs-about.com/ing/zaleplon.html
  • Sonata (Zaleplon) 5 mg and 10 mg capsules official prescribing information and medication guide from the U.S. FDA (revised December 2007): https://www.accessdata.fda.gov/drugsatfda_docs/label...
  • Sonata (Zaleplon) 5 mg and 10 mg capsules prescribing information and medication guide from Pfizer pharmaceutical company (revised 12/2019): http://labeling.pfizer.com/ShowLabeling.aspx?id=710
  • Starnoc (Zaleplon) capsules product information from First Databank, Inc.: https://myhealth.alberta.ca/Health/medications/...
  • Zerene (Zaleplon) capsules summary of product characteristics from European Medicines Agency: https://www.ema.europa.eu/en/documents/product-information/...
  • Zonesta (Zaleplon, Sonata generic by Intas Pharmaceuticals Ltd) 10 mg capsules product information from Practo: https://www.practo.com/medicine-info/zonesta-10-mg-capsule-49610

    Revised: April 2021